| Jason P Palmateer, FNP | |
|
5340 Holy Cross Pkwy, Mishawaka, IN 46545-1470 | |
| (574) 237-1328 | |
| (574) 237-1348 |
| Full Name | Jason P Palmateer |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 23 Years |
| Location | 5340 Holy Cross Pkwy, Mishawaka, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083695332 | NPI | - | NPPES |
| 200862230 | Medicaid | IN | |
| 000000730740 | Other | IN | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71001595B (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Michiana Hematology-oncology P C | 3375513419 | 12 |
News Archive
The same bee and other insect venom shots that doctors use to prevent deadly systemic reactions to insect stings can also tone down large local allergic reactions that, while not dangerous, can be painful and inconvenient, a Johns Hopkins study shows. Results of the study are published in the June 2009 Journal of Allergy and Clinical Immunology.
Kaiser Health News staff writer Mary Agnes Carey writes about the questions stemming from the new health reform law: "David wanted to know how the new health care overhaul law would impact retiree health care coverage.
Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.
› Verified 2 days ago
| Entity Name | Indiana University Health La Porte Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760593776 PECOS PAC ID: 0345147963 Enrollment ID: O20031212000670 |
News Archive
The same bee and other insect venom shots that doctors use to prevent deadly systemic reactions to insect stings can also tone down large local allergic reactions that, while not dangerous, can be painful and inconvenient, a Johns Hopkins study shows. Results of the study are published in the June 2009 Journal of Allergy and Clinical Immunology.
Kaiser Health News staff writer Mary Agnes Carey writes about the questions stemming from the new health reform law: "David wanted to know how the new health care overhaul law would impact retiree health care coverage.
Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.
› Verified 2 days ago
| Entity Name | Michiana Hematology-oncology P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619970183 PECOS PAC ID: 3375513419 Enrollment ID: O20040727001513 |
News Archive
The same bee and other insect venom shots that doctors use to prevent deadly systemic reactions to insect stings can also tone down large local allergic reactions that, while not dangerous, can be painful and inconvenient, a Johns Hopkins study shows. Results of the study are published in the June 2009 Journal of Allergy and Clinical Immunology.
Kaiser Health News staff writer Mary Agnes Carey writes about the questions stemming from the new health reform law: "David wanted to know how the new health care overhaul law would impact retiree health care coverage.
Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason P Palmateer, FNP Po Box 746092, Atlanta, GA 30374-6092 Ph: (574) 334-5400 | Jason P Palmateer, FNP 5340 Holy Cross Pkwy, Mishawaka, IN 46545-1470 Ph: (574) 237-1328 |
News Archive
The same bee and other insect venom shots that doctors use to prevent deadly systemic reactions to insect stings can also tone down large local allergic reactions that, while not dangerous, can be painful and inconvenient, a Johns Hopkins study shows. Results of the study are published in the June 2009 Journal of Allergy and Clinical Immunology.
Kaiser Health News staff writer Mary Agnes Carey writes about the questions stemming from the new health reform law: "David wanted to know how the new health care overhaul law would impact retiree health care coverage.
Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.
› Verified 2 days ago
Kyla M Schauss, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 413 W Mckinley Ave Ste D, Mishawaka, IN 46545 Phone: 574-282-3230 Fax: 574-282-3240 | |
Teresa Marie Dobrzykowski, ANP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 316 Indian Ridge Blvd, Mishawaka, IN 46545 Phone: 800-635-5516 | |
Amy Brown, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5215 Holy Cross Pkwy, Mishawaka, IN 46545 Phone: 574-335-5000 | |
Mrs. Oluyinka Grace Osunnuga, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1540 Trinity Pl, Mishawaka, IN 46545 Phone: 765-674-3321 | |
Shea Lee Warner, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 231 W Day Rd, Mishawaka, IN 46545 Phone: 574-335-4700 | |
Mrs. Blair Renee Herrman, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 524 E Mckinley Ave, Mishawaka, IN 46545 Phone: 574-256-2556 | |
Juanita Marie Roberts, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1625 E Jefferson Blvd, Mishawaka, IN 46545 Phone: 574-255-1400 |